Exploration of Circulating Tumor Cell (CTC) Conversion and CTC0 As Prognostic Biomarkers for Efficacy in TALAPRO-2: Phase 3 Study of Talazoparib (TALA) + Enzalutamide (ENZA) Vs Placebo (PBO) + ENZA As First-Line (1L) Treatment in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc).
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined